- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Carbon nanotubes have significant potential for delivering both imaging and therapeutic agents to tumors, but there is still a need to better quantify how well these rolled-up sheets of graphite can target tumors. Now, thanks to the development of a microscope capable of measuring Raman spectroscopic signals from living mice, researchers have a noninvasive tool to study where carbon nanotubes travel once they are injected into the blood stream.
Reporting its work in the journal Nano Letters, a team of investigators led by Sanjiv Gambhir, M.D., Ph.D., principal investigator of the Center for Cancer Nanotechnology Excellence Focused on Therapy Response (CCNE-TR), based at Stanford University, and Hongjie Dai, Ph.D., also a member of the CCNE-TR, described its use of an optimized Raman microscope to track two different sets of carbon nanotubes as they transited through the body of living mice. One of the nanotubes was covered with the tumor-targeting peptide known as RGD; the other set was used without any added functionality.
Although other investigators have used positron emission tomography (PET) to follow radioactively labeled nanotubes as they move through the body, this technique requires the use of expensive radioisotopes and scanning instruments. To overcome these limitations, the CCNE-TR team took advantage of the fact that carbon nanotubes generate a characteristic Raman emission peak. Earlier this year (click here to see story), Dr. Gambhir and his colleagues described a new type of Raman microscope designed specifically for use in bioimaging studies.
Using this Raman microscope, the investigators were able to track differences in nanotube trafficking between the targeted and untargeted nanotubes. Although both sets of nanotubes showed an initial spike in tumor accumulation, the concentration of untargeted nanotubes in tumors began dropping as early as 20 minutes after injection. In contrast, the tumor concentration of the targeted nanotubes remained elevated for at least 72 hours after injection. In animals treated with the targeted nanotubes, tumors were readily visible as early as 2 hours postinjection and for at least 72 hours. The investigators noted that their results are consistent with those obtained using radioactively labeled nanotubes and PET imaging.
About National Cancer Institute
The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.
Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.
For more information, please click here
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580
Copyright © National Cancer InstituteIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016
New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017
Strength of hair inspires new materials for body armor January 18th, 2017
Self-assembling particles brighten future of LED lighting January 18th, 2017